Multi-modal Large Language Model-Empowered Talk Therapy for Older Adults With ADRD
The purpose of this study is to test the usefulness and the effect of Smart Virtual Reminiscence (SVR) therapy intervention on the Behavioral and Psychological Symptoms of Dementia (BPSD) of patients with Alzheimer's Disease and Related Dementias (ADRD). SVR is designed to help older adults improve their psychological
| Condition(s) | Mild Cognitive Impairment, Dementia, BPSD, BPSD (Behavioral and Psychological Symptoms of Dementia), Reminiscence Therapy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this study is to test the usefulness and the effect of Smart Virtual Reminiscence (SVR) therapy intervention on the Behavioral and Psychological Symptoms of Dementia (BPSD) of patients with Alzheimer's Disease and Related Dementias (ADRD). SVR is designed to help older adults improve their psychological well-being and cognition. This research supports our long-term goal of designing and implementing intelligent interactive systems to improve the health of individuals with ADRD. |
| Who can participate | For the patient: Inclusion criteria: * age ≥ 65 years * diagnosis of MCI (mild cognitive impairment) or mild ADRD * access to a reliable internet connection * community-dwelling * elevated behavioral and psychological symptoms of dementia (BPSD), indicated by a HABC (Healthy Aging Brain Care) monitor score above 14 on caregiver report or self report (indicating elevated levels of BPSD) * presence of one or more specific BPSD behaviors (e.g., agitation, anxiety, depression, apathy, or sleep disturbances) * ability to consent for themselves. Exclusion criteria: * lives in an assisted living facility or nursing home * has moderate to severe ADRD as measured by the Quick Dementia Rating System * has a life expectancy of less than 6 months. For the care partner: Inclusion criteria: * ≥ 21 years |
| Ages | 65 Years |
| Sex | All |
| Lead sponsor | Indiana University |
| Locations | Indianapolis, Indiana, United States |
| Start date | 2025-09-03 |
| NCT ID | NCT07499570 |
| Official listing | https://clinicaltrials.gov/study/NCT07499570 |